***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: BACKGROUND Heparin and direct thrombin inhibitors , such as hirudin , have limitations in the treatment of acute coronary syndromes .  Heparin does not inactivate fibrin-bound thrombin , whereas hirudin fails to block thrombin generation . In contrast , Vasoflux is a novel anticoagulant that inactivates fibrin-bound thrombin and attenuates factor Xa generation . METHODS AND RESULTS Vasoflux is prepared by depolymerization of heparin , restricting molecular size to between 3000 and 8000 Da , and reducing antithrombin affinity by perio date oxidation . Vasoflux catalyzes fibrin-bound thrombin inactivation by heparin cofactor II ( HCII ) and inhibits factor IXa activation of factor X independently of antithrombin and HCII . Compared with other anticoagulants in a thrombogenic extracorporeal circuit , Vasoflux maintains filter patency at concentrations that produce an activated clotting time ( ACT ) of 220 seconds . In contrast , to maintain filter patency , heparin , low-molecular-weight heparin ( LMWH ) , and hirudin require concentrations that produced an ACT of 720 , 415 , and > 1500 seconds , respectively , whereas dermatan sulfate was ineffective at concentrations that produced an ACT of 360 seconds . CONCLUSIONS Vasoflux is more effective than heparin and LMWH because it inactivates fibrin-bound thrombin and is superior to hirudin and dermatan sulfate because it also blocks factor Xa generation 
    Output:
    
Heparin was reported to have a beneficial impact on mortality , graft and wound healing , and pain control .
Given poor study quality , there is no strong evidence to indicate that heparin can improve clinical outcomes in the treatment of burn injury .